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Flavonoids possess several biological and pharmacological activities. Quercetin (Q), a naturally occurring ﬂavonoid, has been
shown to downregulate inﬂammatory responses and provide cardioprotection. However, the mechanisms behind the anti-inﬂam-
matory properties of Q in cardiac cells are poorly understood. In inﬂammation, nitric oxide (NO) acts as a proinﬂammatory
mediator and is synthesized by inducible nitric oxide synthase (iNOS) in response to pro-inﬂammatory agents such as lipopoly-
saccharide(LPS),acausativeagentinmyocardialdepressionduringsepsis.Inthepresentstudy,weevaluatedtheprotectiveeﬀectof
Q on rat cardiac dysfunction during sepsis induced by LPS. Pretreatment of H9c2 cardiomyoblasts with Q inhibited LPS-induced
iNOS expression and NO production and counteracted oxidative stress caused by the unregulated NO production that leads to the
generation of peroxynitrite and other reactive nitrogen species. In addition, Q pretreatment signiﬁcantly counteracted apoptosis
cell death as measured by immunoblotting of the cleaved caspase 3 and caspase 3 activity. Q also inhibited the LPS-induced
phosphorylation of the stress-activated protein kinases (JNK/SAPK) and p38 MAP kinase that are involved in the inhibition of cell
growth as well as the induction of apoptosis. In conclusion, these results suggest that Q might serve as a valuable protective agent
in cardiovascular inﬂammatory diseases.
1.Introduction
Systemic bacterial infection is associated with multiorgan
dysfunctions including heart failure, which is the main
cause of morbidity and mortality in septic patients [1, 2].
Lipopolysaccharides (LPSs), a major constituent of bacterial
outer membrane, have been demonstrated to play a critical
role in the initiation of the pathophysiological cascades [3–
5]. Under septic conditions, excessive LPS activates numer-
ous types of cells upon recognition by toll-like receptor 4
(TLR-4) resulting in enhanced production of proinﬂamma-
tory cytokines that contribute to myocardial dysfunction
[6–8]. Recent studies have shown that cardiomyoblasts
express TLR-4 through which LPS has direct adverse eﬀect
on cardiomyocyte physiology [9, 10]. Activation of TLR-4
b yL P St r i g g e r sN F - κB signaling and results in decreased
cardiomyocyte contractility and substantial expressions of
proinﬂammatory cytokines such as intercellular adhesion
molecule-1 (ICAM-1) [11, 12], tumor necrosis factor-α
(TNF-α)[13,14],andinduciblenitricoxidesynthase(iNOS)
[13]. The increased expression of iNOS, especially in non-
inﬂammatory cells, may have deleterious eﬀects [15–17].
Potential subcellular mechanisms involved in these harmful
consequences include excessive direct reactions of NO with
a wide variety of proteins and enzymes including reactions
with amino, thiol (SH), diazo, and tyrosyl groups, and with
heme and Fe2+ or sulfur centers [18]. Moreover, unregulated
NO production, also associated with oxidative stress, can
result in the generation of peroxynitrite and other reactive
nitrogen species (RNS) that alter protein function via nitra-
tion and oxidation reactions [16, 19, 20]. It has been dem-
onstrated that reducing systemic inﬂammatory response
could improve myocardial function [21]. Activation of mul-
tiple stress signaling processes such as oxidative stress and
mitogen-activated protein kinases (MAPKs) plays pivotal
roles in the pathogenesis of septic cardiac dysfunction [22].
While activation of ERK1/2 MAP-kinase has been identiﬁed
to enhance cell growth and migration, the stress-activated2 Oxidative Medicine and Cellular Longevity
protein kinases JNK/SAPK and p38 MAP-kinase are involved
in the inhibition of cell growth as well as the induction of
apoptosis [23].
Quercetin (Q) is a ﬂavonoid and more speciﬁcally a ﬂa-
vonol that possesses a broad range of pharmacological prop-
erties, including anti-inﬂammatory eﬀects [24], antiprolif-
erative eﬀects [25], and protective eﬀects against oxidative
stress [26]. Foods rich in quercetin include apples, black and
green tea, onions, red wine, red grapes, citrus fruit, broccoli
and other leafy green vegetables, cherries, and a number
of berries including raspberries and cranberries [27]. Nor-
mally, human quercetin plasma concentrations are in the
nanomolar range, but after quercetin intake, they may reach
the micromolar range [28, 29]. A recent study demon-
strated that low to moderate oral dose of quercetin for
two weeks increased plasma quercetin concentrations dose-
dependently in healthy individuals [30], conﬁrming its
bioavailability. In a previous study, we have demonstrated
that Q is uptaken by the cardiomyoblast H9c2 cell line and
counteracts cardiac oxidative stress via both its well-known
antioxidant activity and through the modulation of two key
fundamental protein kinases involved in prosurvival signal-
ing pathways, Akt and ERK1/2 [31]. Moreover, we have
shown that Q is able to strongly upregulate diﬀerent antiox-
idant and phase 2 enzymes in neonatal rat cardiomyocytes
demonstrating its indirect antioxidant activity [32].
In this paper, we evaluated the anti-inﬂammatory eﬀects
of Q in cardiac cells, focusing on the possible mechanisms by
which this polyphenol counteracts LPS-induced inﬂamma-
tory responses.
2.MaterialsandMethods
2.1. Materials. PhosSTOP was purchased from Roche Diag-
nostics (Mannheim, Germany). CelLytic M, 2 ,7 -dichlo-
rodihydroﬂuorescein diacetate (DCFH-DA), mammalian
protease inhibitor mixture, DMEM, fetal bovine serum
(FBS), penicillin, streptomycin, L-glutamine, acetyl-Asp-
Glu-Val-Asp-7-amido-4-methylcoumarin (Ac-DEVD-AMC),
quercetin, and all other chemicals of the highest analytical
grad ew e r epur c hasedfr o mS igmaC he mical(St.L ouis,MO).
2.2. Cell Cultures. Rat embryonic heart-derived myogenic
cell line H9c2 (European Collection of Cell Cultures Salis-
bury, UK) was grown in DMEM supplemented with 10%
heat-inactivated FBS, penicillin (100U/mL), streptomycin
(100mg/mL), and L-glutamine (2mM) in a humidiﬁed
incubator with 5% CO2 at 37◦C. Cells were split 1 to 4 at
subconﬂuence (80%). H9c2 cells were seeded at a density of
5 × 104 cells/cm2 72 hours prior to treatments.
2.3. Measurement of Nitric Oxide Production. Released ni-
trite, a stable product of NO in aqueous medium, was mea-
sured using the Griess Reagent System (Promega, Madison,
WI, USA). Brieﬂy, H9c2 cells were treated with 30μMQf o r
2h o u r sp ri o rt os ti m u l a ti o nwi t h1 0μg/mL LPS for 24 hours.
Attheendofthistimeperiod,theculturemediumwasmixed
with an equal volume of sulfanilamide solution (1% in 5%
phosphoric acid) and of N-1-naphtylethylenediamine dihy-
drochloride solution (0.1% in water). The absorbance was
measuredat540nm.Nitriteconcentrationsweredetermined
from a calibration curve of standard 0.1M sodium nitrite
concentrations 0.5–25μM against absorbance.
2.4. Detection of Intracellular Reactive Oxygen Species. The
formation of ROS was evaluated using a ﬂuorescent probe,
DCFH-DA, as described by Wang and Joseph [33]. Brieﬂy,
H 9 c 2c e l l sw e r ep r e t r e a t e dw i t h3 0μM Q for 24h and then
incubated with 5μM DCFH-DA in PBS for 30min. After
DCFH-DA removal, the cells were stimulated with 10μg/mL
LPS for diﬀerent periods (0.5–24 hours). Cell ﬂuorescence
was measured using 485nm excitation and 535nm emission
with a microplate spectroﬂuorometer (VICTOR3 V Multi-
label Counter, Perkin-Elmer, Wellesley, MA). Intracellular
antioxidant activity was expressed as percentage of control
cells.
2.5. Caspase-3 Activity Assay. The activity of caspase-3 was
measured by hydrolysis of Ac-DEVD-AMC by caspase-3,
resulting in the release of the ﬂuorescent 7-amino-4-methyl-
coumarin moiety (AMC) [34]. H9c2 cells were treated with
30μM Q for 2 hours prior to stimulation with 10μg/mL LPS
for diﬀerent periods (0.5–24 hours). Cells were lysated in
lysis buﬀer (50mM Tris, 0.1% Triton X-100, 150mM NaCl,
2mM EGTA/EDTA, 1mM sodium pyrophosphate, 10mg/
mL phenylmethylsulfonyl ﬂuoride, 1mM sodium vanadate,
50mM sodium ﬂuoride, and 1mg/mL aprotinin) and then
centrifuged 5min at 5,000g and the supernatant was
added to the assay buﬀer (100mM HEPES pH 7.0, 5mM
dithiothreitol, 0.1% CHAPS, 10% sucrose, and 0.15mM Ac-
DEVD-AMC). The speciﬁc cleavage of the ﬂuorogenic pep-
tide Ac-DEVDA-MC was monitored following AMC cleav-
age at 370nm excitation and 455nm emission. One unit is
deﬁned as the amount of enzyme activity cleaving 1.0nmol
of substrate per minute at 25◦C under the conditions
described.
2.6. Western Immunoblotting. H9c2 cells were treated with
30μMQa n da f t e r2h o u r sw e r es t i m u l a t e dw i t h1 0μg/mL
LPS for diﬀerent periods (0.5–24 hours). Cells were washed
with ice-cold PBS and proteins extracted with CelLytic M
cell lysis reagent with mammalian protease inhibitor mixture
(1:100 dilution) and PhosSTOP. Proteins were boiled at
98◦C for 3min in loading buﬀer (62.5mM Tris, pH 6.8
containing 2% SDS, 5% 2-mercaptoethanol, 10% glycerol,
and 0.0025% bromophenol blue). Protein extracts were
separated by SDS-PAGE (20μg/lane) and then transferred
onto nitrocellulose membrane (Hybond-C; GE Healthcare,
Buckinghamshire,UK)at110Vfor90minusingTris-glycine
buﬀer. Membranes were then incubated in a blocking buﬀer
containing 5% (w/v) skimmed milk and incubated with
anti-NOS2, anti-phospho SAPK/JNK (Thr183/Tyr185), anti-
SAPK/JNK, anti-phospho p38 MAPK, anti-p38 MAPK
(Cell Signaling Technology, Beverly, MA), and anti-β-actin
(Sigma), overnight at 4◦C on a three-dimensional rocking
table. The blots were then incubated with goat anti-rabbitOxidative Medicine and Cellular Longevity 3
IgG conjugated to horseradish peroxidase for 60min at
room temperature. The results were visualized by chemi-
luminescence using ECL advance reagent according to the
manufacturer’s protocol (GE Healthcare). Semiquantitative
analysis of speciﬁc immunolabeled bands was performed
using a Fluor S image analyzer (Bio-Rad, Hercules, CA,
USA).
2.7. Protein Concentration. The protein concentration of the
cell lysates was determined by the Bio-Rad Bradford protein
assay (Bio-Rad Laboratories).
2.8. Statistics. Each experiment was performed at least three
times, and all values are represented as means ± SD. One-
way analysis of variance (ANOVA) was used to compare
diﬀerences among groups followed by Bonferroni’s test
(Prism 5, GraphPad Software Inc., San Diego, CA, USA).
Values of P<0.05 were considered as statistically signiﬁcant.
3. Results
3.1. Eﬀect of Q on iNOS Expression and NO Production.
The ﬁrst aim of the study was to identify the eﬀect of LPS
treatment on iNOS expression (Figure 1). LPS treatment
(10μg/mL) of H9c2 cells for 0.5 hours did not inﬂuence
iNOS protein expression. On the contrary, LPS stimulation
for 2 and 24 hours was able to signiﬁcantly induce iNOS. In
particular, LPS increased the enzyme protein expression in
a time-dependent manner (r = 0.9888, P<0.05). Treament
with 30μM Q alone for 2 hours had no eﬀect on iNOS
protein expression, while pretreatment with Q, prior to
LPS exposure, was able to signiﬁcantly reduce iNOS protein
expression at each LPS stimulation time.
We next evaluated total nitrite release as an indicator of
NO production (Figure 2). As at 24 hours LPS stimulation
had the strongest eﬀect on iNOS protein expression, we
used this time to stimulate H9c2. In agreement with the
previous results, LPS signiﬁcantly increased the release of
NO in the culture medium, 30μM Q alone did not inﬂuence
NO production, and pretreatment with 30μMQb e f o r eL P S
stimulation signiﬁcantly reduced NO production to level
comparable to control cells.
3.2. Eﬀect of Q on Intracellular ROS Production. To verify
if the increase in RNS was accompanied by a concomitant
increase in ROS production, we evaluated intracellular ROS
accumulation in H9c2 cells stimulated with LPS for diﬀerent
periods in the presence or the absence of 30μMQ( Figure 3).
Intracellular ROS levels were signiﬁcantly increased in cells
stimulated with LPS for 24 hours compared to control cells,
as indicated by the increase in DCF ﬂuorescence. However,
the increase in DCF ﬂuorescence was signiﬁcantly decreased
by Q pretreatment suggesting that Q was capable of reducing
intracellular ROS accumulation following LPS stimulation.
3.3. Eﬀe c to fQo nL P S - I n d u c e dA p o p t o s i si nH 9 c 2C e l l s .Q
demonstrated antiapoptotic eﬀects in diﬀerent cell types,
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Figure 1: Eﬀect of Q on iNOS expression in LPS-stimulated H9c2
cells. Cells were pretreated with 30μM Q for 2 hours before stim-
ulation with 10μg/mL LPS. After the indicated time points, cells
wereharvestedandlysed.Crudehomogenates(20μg)wereimmun-
oblotted with an antibody that detects endogenous levels of iNOS
(NOS2). Equal loading was veriﬁed with an anti-β-actin antibody.
Densitometric analysis of the protein bands was performed using
Bio-Rad Quantity One 1-D Analysis software. Each column rep-
resents the mean ± SD of three independent experiments. Data
were analyzed by one-way ANOVA followed by Bonferroni’s test.
∗P<0.05 compared to Control; ◦P<0.05 compared to the
corresponding LPS exposure times.
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Figure 2: Eﬀect of Q on NO production in LPS-stimulated H9c2
cells. Cells were pretreated with 30μM Q for 2 hours before stim-
ulation with 10μg/mL LPS for 24 hours. After the treatment, the
culture medium was collected for NO assay. The concentration of
NOwasdeterminedbytheGriessreagentusingNaNO2 asstandard.
Each column represents the mean±SD of three independent
experiments. Data were analyzed by one-way ANOVA followed by
Bonferroni’s test. ∗P<0.05 compared to Control; ◦P<0.05
compared to LPS.4 Oxidative Medicine and Cellular Longevity
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Figure 3: Eﬀect of Q on intracellular ROS production in LPS-
stimulated H9c2 cells. Cells were pretreated with 30μMQf o r2
hoursbeforestimulationwith10μg/mLLPS.After24hintracellular
ROS were measured using the peroxide-sensitive ﬂuorescent probe
DCHF-DA. Each column represents the mean ± SD of three
independent experiments. Data were analyzed by one-way ANOVA
followed by Bonferroni’s test. ∗P<0.05 compared to Control;
◦P<0.05 compared to LPS.
therefore, we next investigated whether Q protects car-
diomyoblasts from LPS-induced apoptosis. H9c2 cells were
pretreated with 30μM Q before exposure to 10μg/mL LPS
for diﬀerent exposure times and cleaved caspase 3 protein
expression (Figure 4) and caspase 3 activity (Figure 5)w e r e
evaluated. Immunoblot analyses showed that stimulation
with LPS for 24 hours induced a signiﬁcant cleavage of
caspase3inrespecttocontrolcells,while0.5and2hours LPS
exposure times had no eﬀect on cleaved caspase 3. Pretreat-
ment with Q before LPS stimulation was able to strongly
reduce cleavage of caspase 3 to level comparable to control
cells. Q alone did not modify caspase 3 cleavage. These data
wereconﬁrmedbycaspase3activityassay.Only24hoursLPS
stimulation was able to signiﬁcantly increase caspase 3 activ-
ity and pretreatment with Q signiﬁcantly reduced caspase 3
activity to level comparable to control cells, demonstrating
the antiapoptotic eﬀect of Q against LPS-induced damage.
3.4. Eﬀect of Q on LPS Activation of MAPK in H9c2 Cells. To
better clarify the mechanisms behind Q protection against
LPS induced apoptosis, we investigated the role of Q in
the modulation of two fundamental proapoptotic signaling
pathways in H9c2 cells: JNK and p38 MAPK. H9c2 cells
were pretreated with 30μM Q before exposure to 10μg/mL
LPS for diﬀerent exposure times and cell lysates were
analyzed by immunoblotting with anti-phospho-p38 and
anti-p38 antibodies (Figure 6) or anti-phospho-JNK and
anti-JNK antibodies (Figure 7). LPS treatment for 0.5 and
2 hours signiﬁcantly activated p38 MAPK as measured by
phospho/total p38 ratio, with the highest increase at 0.5
hours. At the longest exposure time p38, MAPK was no
longer activated as phospho/total p38 ratio was comparable
tocontrolcells.Qwasabletosigniﬁcantlyinhibit p38 MAPK
activation.LPStreatmentfor0.5hourssigniﬁcantlyactivated
JNK as measured by phospho/total JNK ratio, while after
2 and 24 hours LPS stimulation did not inﬂuence JNK
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Figure 4: Eﬀect of Q on cleaved caspase 3 protein expression in
LPS-stimulated H9c2 cells. Cells were pretreated with 30μMQf o r
2hoursbeforestimulationwith10μg/mLLPS.Attheindicatedtime
points, cells were harvested and lysed. Crude homogenates (20μg)
were immunoblotted with an antibody that detects endogenous
levels of cleaved caspase 3. Equal loading was veriﬁed with an anti-
β-actin antibody. Densitometric analysis of the protein bands was
performed using Bio-Rad Quantity One 1-D Analysis software.
Each column represents the mean ± SD of three independent
experiments. Data were analyzed by one-way ANOVA followed by
Bonferroni’s test. ∗P<0.05 compared to Control; ◦P<0.05
compared to the corresponding LPS exposure times.
phosphorylation.QwasabletosigniﬁcantlyreduceJNKacti-
vation after 0.5 hours LPS exposure time at level comparable
to control cells.
4. Discussion
In this study, we have evaluated the anti-inﬂammatory role
of Q in H9c2 cells demonstrating that this polyphenol atten-
uated LPS-induced inﬂammatory events inhibiting iNOS
induction,reducingNOproductionandoxidativestress,and
counteracting apoptosis through the modulation of two key
protein kinases p38 MAPK and JNK.
A range of clinical conditions are associated with a
dysregulationofinﬂammatoryresponses. Althoughthemost
common of these is sepsis, high concentrations of cytokines
are also generated by ischemia-reperfusion, trauma, acute
rejection, antigen-speciﬁc immune responses, and diﬀerent
acute inﬂammatory states [35]. Several studies suggest a
beneﬁcial eﬀect for cardiac dysfunction through inhibition
of cardiac inﬂammatory processes in sepsis [13].
LPS of Gram-negative bacteria has been recognized as a
causative agent in myocardial depression during sepsis [36].Oxidative Medicine and Cellular Longevity 5
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Figure 5: Eﬀect of Q on caspase 3 activity in LPS-stimulated
H9c2 cells. Cells were pretreated with 30μM Q for 2 hours before
stimulation with 10μg/mL LPS. At the indicated time points,
caspase 3 activity was measured spectroﬂuorimetrically in cell
lysates as reported in Section 2.Each column representsthemean ±
SD of three independent experiments. Data were analyzed by one-
way ANOVA followed by Bonferroni’s test. ∗P<0.05 compared to
Control; ◦P<0.05 compared to the corresponding LPS exposure
times.
It has been shown that the inﬂammatory responses induced
by LPS in cardiomyocytes are characterized by an increased
production of ROS which leads to the activation of tran-
scription factors and intracellular signaling pathways and to
the induction of inﬂammatory mediators, including TNF-α,
ICAM-1, and iNOS. All of these mediators may be involved
in the depression of cardiac function [13, 37, 38]. In the
cardiovascular system, NO produced by iNOS is a major
pathophysiologic mediator of septic shock [39] and has been
shown to mediate the negative inotropic eﬀects of cytokines
[40]. In agreement with previous studies, performed using
cardiomyocytesstimulated withLPSforatleast20h[41,42],
we demonstrated that iNOS protein expression and NO pro-
ductionweresigniﬁcantlyincreasedinLPS-stimulatedH9c2.
On the contrary, a study of Chen et al. [43] demonstrated an
increase in iNOS mRNA level while NO production was not
inﬂuenced by a 4h LPS stimulation in rat cardiomyoblasts.
ThisdiscrepancycouldbeascribedtothelowerLPSexposure
time that is probably too short to signiﬁcantly increase NO
in the culture medium. In our study, Q treatment was able to
signiﬁcantly reduce both iNOS expression and NO produc-
tion.
AsNOmayreactwithROSsuchasthesuperoxideradical
to yield the highly reactive oxidant species peroxynitrite,
leading to more aggressive oxidative and nitrosative stress
[44], we evaluated the intracellular ROS production in
LPS-stimulated H9c2 cells. As expected, LPS signiﬁcantly
increased intracellular ROS level while Q pretreatment was
able to reduce this production to level comparable to control
cells. We previously demonstrated the ability of Q to reduce
oxidative stress in H9c2 cells [31] and in rat cardiomyocytes
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Figure 6: Eﬀect of Q on p38 MAPK activation in LPS-stimulated
H9c2 cells. Cells were pretreated with 30μM Q for 2 hours before
stimulation with 10μg/mL LPS. At the indicated time points, cells
wereharvestedandlysed.Crudehomogenates(20μg)wereimmun-
oblotted with anti-phospho-p38 and anti-p38 antibodies. Equal
loading was veriﬁed with an anti-β-actin antibody. Densitometric
analysis of the protein bands was performed using Bio-Rad Quanti-
ty One 1-D Analysis software. Each column represents the mean ±
SD of three independent experiments. Data were analyzed by one-
way ANOVA followed by Bonferroni’s test. ∗P<0.05 compared to
Control; ◦P<0.05 compared to the corresponding LPS exposure
time.
[32] through both a direct and indirect antioxidant mecha-
nisms.
The action of NO has been related to the induction of
programmed cell death, or apoptosis, in various cells [45].
The capacity of NO to induce apoptosis was ﬁrst appreciated
by Albina et al. [46], who showed that NO caused apoptosis
in macrophages. Many reports suggest that during the
ischemia-reperfusion event, NO mediates tissue injury [47,
48]. Moreover, induction of iNOS by cytokines in pri-
mary rat cardiac myocytes was associated with an increased
myocytes apoptosis, which was ameliorated by the adminis-
tration of an inhibitor of NO synthase, which blocked the
expression of iNOS in response to cytokines [45]. These
results suggest that NO is markedly involved in cardiomyo-
pathy, which leads to the contribution of impaired cardiac
function. Our results demonstrated that Q was able to
counteract LPS-induced apoptosis by inhibiting caspase-3
activation and signiﬁcantly reducing caspase-3 activity.
Diﬀerent studies have demonstrated that the mechanism
underlying the cytoprotection of Q may be mediated by6 Oxidative Medicine and Cellular Longevity
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Figure 7: Eﬀe c to fQo nJ N Ka c t i v a t i o ni nL P S - s t i m u l a t e dH 9 c 2
cells. Cells were pretreated with 30μM Q for 2 hours before stim-
ulation with 10μg/mL LPS. At the indicated time points, cells were
harvestedandlysed.Crudehomogenates(20μg)wereimmunoblot-
tedwithanti-phospho-JNKandanti-JNKantibodies.Equalloading
was veriﬁed with an anti-β-actin antibody. Densitometric analysis
of the protein bands was performed using Bio-Rad Quantity One
1-D Analysis software. Each column represents the mean ± SD of
three independent experiments. Data were analyzed by one-way
ANOVA followed by Bonferroni’s test. ∗P<0.05 compared to
Control; ◦P<0.05 compared to the corresponding LPS exposure
time.
inhibition of NF-κBa c t i v a t i o n[ 44, 49, 50], which controls
the expression of inﬂammatory mediators [51]. A crucial
step in the activation of NF-κB is the degradation of IκBa
[52]. LPS stimulates the canonical NF-κB activation pathway
through degradation of IκBa and phosphorylation of NFκB
p65 subunit [53, 54], NF-κB p65 subsequently translocates
from the cytoplasm to the nucleus and, in turn, triggers a
large amount of genes encoded for inﬂammatory mediators
[54].
The mitogen-activated protein kinase (MAPK) family,
including extracellular signal-regulated c-Jun N-terminal
kinases 1 and 2 (JNK) and p38 MAP kinases, plays an impor-
tant role in cell fate decisions and has been implicated in
death/survival signaling in cardiac myocytes [55]. Evidence
alsoindicatesthatROScontributetoLPS-stimulatedMAPKs
signaling pathways in myocardial cells [13]. These ﬁndings
are in line with the crucial role of MAPKs signaling and
oxidative stress in sepsis-induced myocardial contractile dys-
function [13, 37, 38]. Data reported in this paper demon-
strated that LPS stimulation activates both p38 MAPK and
JNK. In particular, JNK activation was quick and transient
and after 2h LPS stimulation JNK phosphorylation was
comparable to control cells, while p38 MAPK activation
lasted for at least 2h. Our data are in agreement with the
results of Peng et al. [56] that demonstrated an immediate
and transient increase in p38 MAPK activation after LPS
stimulation, which was followed by TNF-α production in
the myocardium and the inhibition of p38 MAPK activation
improved cardiac function and survival during endotoxemia
in mice. Activation of JNK signal transduction cascades
has been implicated in the regulation of hypertrophic and
apoptotic responses in the myocardium [57]. Peng et al. [58]
showed that LPS increases JNK activation in cultured cardio-
myocytes. It has been demonstrated that the activation of
JNK/SAPK is crucial for NO toxicity in H9c2 cardiac muscle
cells [59], moreover, Liu et al. [60] observed that incubation
of LPS-treated myocardial cells with the JNK1/2 inhibitor
SP600125 resulted in marked inhibition of LPS-induced
phosphorylationofIκB,degradationofIκBandupregulation
of TNF-α, leading to myocardial apoptotic responses.
Q pretreatment was able to reduce the activation of the
two kinases to values comparable to control cells, demon-
strating that the antiapoptotic eﬀect of Q could be also
mediated by the modulation of p38 MAPK and JNK whose
detrimental role in sepsis has been largely demonstrated.
In conclusion, Q inhibited iNOS induction in LPS-stim-
ulated H9c2 cells in a time-dependent manner, reduced NO
production, and counteracted LPS-induced apoptosis. This
protective eﬀect might be mediated by the suppression of the
activation of p38 MAPK and JNK. Therefore, these results
suggest that Q might serve as a valuable protective agent in
cardiovascular and inﬂammatory diseases.
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